A Phase Ib/II Study of LEE011 in Combination With Fulvestrant and BYL719 or BKM120 in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Recurrent or Advanced Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 May 2018
At a glance
- Drugs Alpelisib (Primary) ; Buparlisib (Primary) ; Ribociclib (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 06 May 2018 This trial has been Discontinued in Italy.
- 23 Feb 2018 Planned End Date changed from 1 Sep 2017 to 15 Jun 2018.
- 23 Feb 2018 Planned primary completion date changed from 1 Sep 2017 to 15 Jun 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History